Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source

Trey Thoelcke

Mon, August 17, 2026 at 4:10 PM GMT+3 3 min read

ATTO -0.05%

Quick Read

ATTO trades near $20, already 9% below its IPO print, with the entire pipeline built around blocking IL-31, dubbed the 'itch cytokine.'
Founded in 2023 and backed by $256 million raised, Attovia's next Phase 1 trial won't start until 2027, leaving commercial revenue years away.
It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor)

Attovia Therapeutics (NASDAQ:ATTO) has arrived on public markets with a pipeline built entirely on one bet: that a biparatopic antibody platform called Attobody can turn well-validated immunology targets into next-generation biologics. The lead asset is aimed at the cytokine behind chronic itch.

nicolas_ / Getty Images

Shares last changed hands at $19.86, up 3.6% on the session, giving Attovia a market capitalization of roughly $287.9 million. With only eight trading days of history, the stock has drifted 9.32% lower from its $21.90 early print.

The IL-31 Itch Thesis

The centerpiece is ATTO-1310. Per the S-1, it is a "novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31" and is currently in a Phase 1 clinical trial in healthy volunteers and patients. Attovia is developing it for chronic pruritus and high-itch atopic dermatitis, positioning against a cytokine the filing describes it thus: "IL-31 commonly known as the 'itch cytokine.' IL-31 upregulated in host of pruritic diseases."

The label ambition extends to chronic pruritus of unknown origin and cholestatic pruritus in primary biliary disease.

Platform and Pipeline

Attobody was in-licensed from Alamar Biosciences and uses an evolution-driven, high-throughput process to generate biparatopic biologics. Behind ATTO-1310 sit two additional candidates:

SoFi Active Invest is offering a limited-time promotion. Open an account, fund it with $50 or more, and you could receive up to $3,000 in complimentary stock for Active Invest accounts. See for yourself by clicking here now.

ATTO-2306: a bispecific targeting IL-13 and IL-31, in IND-enabling studies, with a Phase 1 trial expected to commence in the first half of 2027.
ATTO-1091: a trispecific Attobody-based Fc fusion protein designed to block TL1A, IL-23 and integrin a4ß7 simultaneously, aimed at inflammatory bowel disease.

The company, founded in 2023, disclosed it raised $255.8 million as of March 31, 2026. That runway that included a $90 million Series C reported ahead of the offering. Underwriters on the IPO include Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets, and LifeSci Capital.

Risks the Filing Flags

Attovia is classified as an emerging growth company and smaller reporting company, meaning reduced disclosure requirements. The prospectus also cautions that revenue depends on commercial sales of ATTO-1310, ATTO-2306, ATTO-1091, or future product candidates, if approved, and that further development of the Attobody platform is required. Product liability, trial timelines, and manufacturing partnerships all appear in the risk factors.

What to Watch

The nearest-term catalysts are ATTO-1310 Phase 1 readouts in pruritus indications, followed by the ATTO-2306 IND clearance targeted for the first half of 2027. For a clinical-stage company with a newly issued float and no near-term commercial revenue, those data readouts will define whether the Attobody thesis can translate from a platform pitch into a franchise.

Want Up To $3,000 In Stock? SoFi Is Giving New Active Invest Users Complimentary Stock

Looking to grow your money but unsure where to begin? SoFi Active Invest is offering a limited-time promotion—open a new Active Invest account, fund it with $50 or more, and you could receive up to $3,000 in complimentary stock.

From $0 commission trading3 to fractional shares4 and automated investing, this app is designed to simplify investing for everyone, whether you're just starting or already experienced. Its easy to sign up and secure your bonus.(Sponsor)

Contact editorial@247wallst.com for any questions or corrections.